This article was originally published on ETFTrends.com.
The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is establishing a reputation for being one of the best-performing healthcare ETFs, a legacy forged over its multi-year lifespan, not just a few weeks.
One of the driving forces behind ARKG’s enviable long-term track records its the manager’s ability to identify disruptive forces in the healthcare and genomics arenas. The intersection of precision medicine and genomics could be the next growth frontier for ARKG investors.
“Increasingly, clinicians are tailoring treatments to a patient’s specific genetic mutations,” said ARK analyst Simon Barnett in a recent note. “While the number of precision therapies targeting these mutations has grown, only recently have costs dropped to a low enough level that physicians can sequence an individual’s genomic profile and identify his or her mutations.”
ARKG includes companies that merge healthcare with technology and capitalize on the revolution